LB Pharmaceuticals Inc Common Stock
NASDAQ:LBRXBiotechnology
-$0.39 today
- Market cap
- $1.30B
- Beta
- 0.71
- P/E (TTM)
- -21.4
- EPS (TTM)
- -$1.39
Volume 0.36M
Average 0.23M
LBRX Interest Expense
Cost of servicing the company's debt during the period.
LB Pharmaceuticals Inc Common StockNASDAQ: LBRX
Interest Expense · Q1 FY2026 · quarter ended Mar 2026
Interest expense turns positive
Q1 FY2026 interest expense was $0, compared with -$206.5K a year earlier. Trailing-twelve-month interest expense was -$206.5K.
Context
- Interest expense increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly interest expense holds near $0 or moves back toward the trailing-twelve-month quarterly average of -$51.63K.
Sources:Income StatementText generated from reported figures; not investment advice.
Interest Expense history
USD · from the income statement
- Latest · FY2025
- 0 USD
- Year-over-year change
- —
| Period | Period end | Interest Expense | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | — |
| FY2024 | 2024-12-31 | 0 | -100.0% |
| FY2023 | 2023-12-31 | 4.83M | +124.3% |
| FY2022 | 2022-12-31 | 2.15M | — |
Interest Expense vs competitors
How LBRX compares with its peers on the latest reported figures
- LBRX's LTM Mar 2026 interest expense of -$206.5K is the lowest of the 10 companies compared; the peer median is $0.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
DFTXDefinium Therapeutics, Inc. | LTM Sep 2026 | $13.32M | +173.6% | +54.2% | — |
NMRANeumora Therapeutics, Inc. Common Stock | LTM Mar 2026 | $4.64M | — | — | — |
| LTM Mar 2026 | $2.42M | +48.5% | — | — | |
| LTM Mar 2026 | $369K | -48.5% | — | — | |
| LTM Sep 2026 | $0 | — | — | 0.0% | |
| LTM Jun 2026 | $0 | — | — | 0.0% | |
RAPPRapport Therapeutics, Inc. Common Stock | LTM Mar 2026 | $0 | — | — | 0.0% |
| LTM Mar 2026 | $0 | — | — | — | |
| LTM Jun 2026 | $0 | — | — | — | |
LBRXLB Pharmaceuticals Inc Common Stock | LTM Mar 2026 | -$206.5K | — | — | — |
SPTXSeaport Therapeutics, Inc. Common Stock | — | — | — | — | — |
| Peer median (excluding LBRX) | $0 | +48.5% | +54.2% | 0.0% | |
Competitors are the stored peer set for LBRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — |
| Research & Development | 1.35M | 7.85M | 51.17M | 16.74M |
| Selling, General & Admin | 1.46M | 3.53M | 13.66M | 13.66M |
| Operating Expenses | 2.81M | 11.38M | 64.83M | 30.4M |
| Depreciation & Amortization | 2K | 4K | 91K | 321K |
| EBITDA | (12.19M) | (1.45M) | (63.01M) | (24.88M) |
| EBITDA Margin | — | — | — | — |
| Operating Income | (2.81M) | (11.38M) | (64.83M) | (30.4M) |
| Operating Margin | — | — | — | — |
| Interest Income | 73K | 811K | 1.72M | 3.92M |
| Interest Expense | 2.15M | 4.83M | 0 | 0 |
| Other Income / Expenses | (11.54M) | 5.1M | 1.73M | 5.2M |
| Income Before Tax | (14.35M) | (6.27M) | (63.1M) | (25.2M) |
| Pre-Tax Margin | — | — | — | — |
| Income Tax Expense | 1K | 1K | 1K | 1K |
| Net Income | (14.35M) | (6.28M) | (63.1M) | (25.21M) |
| Net Margin | — | — | — | — |
| EPS (Basic) | (4.05) | (1.77) | (17.83) | (1.00) |
| EPS (Diluted) | (4.05) | (1.77) | (17.83) | (1.00) |
| Weighted Avg Shares | 3.54M | 3.54M | 3.54M | 25.3M |
| Weighted Avg Shares (Diluted) | 3.54M | 3.54M | 3.54M | 25.3M |
LB Pharmaceuticals Inc Common Stock
NASDAQ:LBRX
Intrinsic Alpha fair value
Locked
Current Price
$40.06
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.